Coherus Biosciences Inc. (CHRS) 35.40 $CHRS
Charming Shoppes Shares Up 43.0% Since SmarTrend's Buy Recommendation (CHRS)
Comtex SmarTrend(R) - Wed Jul 29, 9:51AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 43.02% as of today's recent price of $35.82.
CHRS: 35.40 (+0.73)
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10
GlobeNewswire - Tue Jul 28, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, August 10, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2015 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frederic Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
CHRS: 35.40 (+0.73)
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles
M2 - Tue Jul 21, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tfffq/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Amgen Inc. - Avesthagen Limited - Avexxin AS - Biocon Limited - Biotie Therapies Corp. - Can-Fite BioPharma Ltd. - Celltrion, Inc. - Circassia Pharmaceuticals plc - Coherus BioSciences, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Epirus Biopharmaceuticals, Inc. - Forward Pharma A/S - Galectin Therapeutics, Inc. - Genor BioPharma Co., Ltd. - Idera Pharmaceuticals, Inc. - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - LEO Pharma A/S - Lipidor AB - Mabion SA - Maruho Co., Ltd. - Momenta Pharmaceuticals, Inc. - Oncobiologics, Inc. - Pfizer Inc. - Promius Pharma, LLC - Protalix BioTherapeutics, Inc. - Provectus Biopharmaceuticals, Inc. - R-Tech Ueno, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - (betamethasone dipropionate bexarotene) - (calcipotriene betamethasone dipropionate) - (calcipotriene betamethasone) - adalimumab biosimilar - AM-001 - ASKP-1240 - AVX-001 - betamethasone maxacalcitol - bimekizumab - brodalumab - BTT-1023 - calcipotriene - CF-101 - CIR-001 - CT-327 - dalazatide - DFD-01 - DFD-06 - dimethyl fumarate - DLX-105 - DRM-02 - etanercept biosimilar - GK-664S - GR-MD-02 - guselkumab - IDP-118 - IMO-8400 - infliximab biosimilar - INV-103 - KD-025 - LEO-32731 - LP-0113 - M-801801 - MOL-4239 - MOL-4249 For more information visit http://www.researchandmarkets.com/research/7t..._psoriasis
PFE: 35.82 (-0.29), GALT: 2.56 (-0.09), AMGN: 176.44 (+1.64), MNTA: 23.12 (+1.07), CHRS: 35.40 (+0.73), PVCT: 0.50 (unch), CANF: 1.88 (-0.06), JNJ: 100.52 (+0.72), IDRA: 3.32 (-0.17), DERM: 22.08 (-0.38), FWP: 33.05 (+0.08)
37.6% Return Seen to Date on SmarTrend Charming Shoppes Call (CHRS)
Comtex SmarTrend(R) - Tue Jul 14, 4:46PM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 37.55% as of today's recent price of $34.45.
CHRS: 35.40 (+0.73)
Coherus Biosciences (CHRS) in Focus: Stock Surges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 13, 8:18AM CDT
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares surge around 11% on the day.
ACHN: 8.11 (unch), CHRS: 35.40 (+0.73)
$1.5 Trillion Reasons to Invest in These Companies
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 12, 10:02AM CDT
Source: Flickr user Bill Brooks Runaway healthcare spending poses a major risk to Americans, but generic drugs have been responsible for cutting $1.5 trillion in costs over the past 10 years, according to IMS Health data. That's an astounding...
BIIB: 335.41 (+5.03), ESRX: 90.75 (+1.44), BAX: 42.13 (+1.82), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), MNTA: 23.12 (+1.07), NVS: 103.25 (-0.32), CHRS: 35.40 (+0.73)
Global Neutropenia Pipeline Report 2015 - 20 Companies & 14 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d42lrx/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Apotex, Inc. - Biocon Limited - Biosidus S.A. - Cellerant Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Coherus BioSciences, Inc. - CSL Limited - Gamida Cell Ltd. - Genexine, Inc. - Inbiopro Solutions Pvt. Ltd. - Ligand Pharmaceuticals, Inc. - NAL Pharmaceuticals Ltd. - Pfenex Inc. - Richter Gedeon Nyrt. - Sandoz International GmbH - Taiho Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Therapeutic Proteins International, LLC - Toko Pharmaceutical Industries Co., Ltd. - USV Limited Drug Profiles - (piperacillin sodium tazobactam sodium) - ACN-8337 - CSL-324 - filgrastim (recombinant) - GC-003 - granulocyte colony-stimulating factor biobetter - GXG-3 - IBPB-004IG - LG-7455 - lipegfilgrastim - pegfilgrastim - romyelocel-L - ST-7 - tamibarotene For more information visit http://www.researchandmarkets.com/research/d4...eutropenia
TEVA: 71.19 (+0.50), PFNX: 20.56 (-0.30), CHRS: 35.40 (+0.73)
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), MNTA: 23.12 (+1.07), CHRS: 35.40 (+0.73), JNJ: 100.52 (+0.72), ALDR: 44.74 (-0.43), ABBV: 70.30 (+0.35), NVS: 103.25 (-0.32), CELGZ: 2.01 (+0.07)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 100.52 (+0.72), ALDR: 44.74 (-0.43), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), NVS: 103.25 (-0.32), CHRS: 35.40 (+0.73), CELGZ: 2.01 (+0.07)
14.8% Return Seen to Date on SmarTrend Charming Shoppes Call (CHRS)
Comtex SmarTrend(R) - Tue Jul 07, 12:03PM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 14.75% as of today's recent price of $28.74.
CHRS: 35.40 (+0.73)
Shares of CHRS Up 13.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 30, 11:47AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 1 month, Charming Shoppes has returned 13.16% as of today's recent price of $28.34.
CHRS: 35.40 (+0.73)
InsiderInsights.com Daily Round Up 6/16/15: RAI, GAIN, NPS, VRX
InsiderInsights - at Seeking Alpha - Wed Jun 17, 1:54PM CDT
RAI: 87.96 (+0.13), UCP: 7.39 (-0.05), CLMS: 12.00 (-0.08), DEA: 15.63 (-0.03), ANET: 84.59 (+1.65), VRX: 262.52 (+2.54), NATR: 13.02 (+0.07), COTY: 28.32 (+0.83), SAM: 233.22 (-1.56), DHIL: 190.80 (+0.54), SERV: 36.45 (+0.23), PCLN: 1,351.21 (+67.22), CHRS: 35.40 (+0.73), DXCM: 85.95 (+1.02), COMM: 31.54 (+0.42), RCPT: 228.97 (+0.97), RNG: 19.44 (+0.05), MNR: 9.95 (-0.05), GAIN: 7.90 (unch)
Charming Shoppes Shares Up 8.2% Since SmarTrend's Buy Recommendation (CHRS)
Comtex SmarTrend(R) - Thu Jun 11, 10:33AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 3 weeks, Charming Shoppes has returned 8.25% as of today's recent price of $27.11.
CHRS: 35.40 (+0.73)
Coherus Biosciences (CHRS) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 11, 8:17AM CDT
Coherus Biosciences (CHRS) is Overbought: Is A Drop Coming?
CHRS: 35.40 (+0.73)
Febrile Neutropenia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 10:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cgxl67/febrile) has announced the addition of the "Febrile Neutropenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Apotex - Biocon - Coherus BioSciences - Pfizer - Richter Gedeon - Sandoz International - Teva Pharmaceutical Industries - Therapeutic Proteins International - Xenetic Biosciences For more information visit http://www.researchandmarkets.com/research/cgxl67/febrile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TEVA: 71.19 (+0.50), CHRS: 35.40 (+0.73)
Coherus BioSciences to Present at Jefferies Healthcare Conference on June 3
GlobeNewswire - Wed May 27, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3rd at 3:00 pm ET in New York City.
CHRS: 35.40 (+0.73)
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results
GlobeNewswire - Mon May 11, 3:05PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the first quarter ended March 31, 2015.
CHRS: 35.40 (+0.73)
Next Week In Biotech: ASCO Abstracts, Pernix PDUFA, Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 8:00AM CDT
Biotech investors have plenty to look forward to next week, as the American Society of Clinical Oncology will release presentation abstracts for its upcoming annual meeting, while a PDUFA date is expected for Pernix (NASDAQ: PTX ). Last week's flood...
ARWR: 6.77 (+0.74), CLSN: 2.21 (-0.05), CMRX: 57.43 (+1.19), SCLN: 9.15 (+0.04), ELOS: 10.15 (-0.20), ZGNX: 19.13 (-0.36), LGND: 111.25 (+1.94), DEPO: 30.84 (+0.04), IMUC: 0.46 (-0.01), ARGS: 6.05 (-0.01), OPXA: 0.39 (-0.01), FLML: 21.97 (-1.08), OGXI: 3.05 (-0.14), CTSO: 6.82 (+0.02), DARA: 0.82 (+0.02), ICCC: 10.49 (+0.42), ICPT: 260.13 (+0.04), PBYI: 90.21 (+1.76), BDSI: 7.81 (+0.17), ACT: 298.98 (-2.94), DRNA: 11.54 (-0.43), BSTC: 63.13 (-1.84), PAHC: 39.31 (+0.62), PTX: 4.72 (-0.18), XON: 68.71 (+3.37), FOMX: 11.03 (+0.02), CLDN: 1.22 (unch), BIOC: 2.40 (+0.03), CHRS: 35.40 (+0.73), DSCI: 7.01 (-0.01), INO: 7.18 (+0.03), FMI: 21.17 (-0.19), CYTX: 0.42 (unch), ANTH: 10.94 (+0.23), ATHX: 1.04 (-0.03), ALQA: 5.14 (+0.07), ENDP: 85.85 (+0.74), DPLO: 47.75 (-1.98), GALT: 2.56 (-0.09), RPRX: 8.01 (+0.44), OMER: 15.77 (+0.15), HALO: 23.42 (+0.11), IDRA: 3.32 (-0.17), CF: 61.62 (+1.09), BTX: 3.06 (-0.05), APRI: 1.30 (-0.10), ATRS: 2.07 (-0.02), KPTI: 22.35 (+0.65)
Charming Shoppes Shares Up 43.0% Since SmarTrend's Buy Recommendation (CHRS)
Comtex SmarTrend(R) - Wed Jul 29, 9:51AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 43.02% as of today's recent price of $35.82.
CHRS: 35.40 (+0.73)
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10
GlobeNewswire - Tue Jul 28, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, August 10, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2015 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frederic Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
CHRS: 35.40 (+0.73)
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles
M2 - Tue Jul 21, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tfffq/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Amgen Inc. - Avesthagen Limited - Avexxin AS - Biocon Limited - Biotie Therapies Corp. - Can-Fite BioPharma Ltd. - Celltrion, Inc. - Circassia Pharmaceuticals plc - Coherus BioSciences, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Epirus Biopharmaceuticals, Inc. - Forward Pharma A/S - Galectin Therapeutics, Inc. - Genor BioPharma Co., Ltd. - Idera Pharmaceuticals, Inc. - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - LEO Pharma A/S - Lipidor AB - Mabion SA - Maruho Co., Ltd. - Momenta Pharmaceuticals, Inc. - Oncobiologics, Inc. - Pfizer Inc. - Promius Pharma, LLC - Protalix BioTherapeutics, Inc. - Provectus Biopharmaceuticals, Inc. - R-Tech Ueno, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - (betamethasone dipropionate bexarotene) - (calcipotriene betamethasone dipropionate) - (calcipotriene betamethasone) - adalimumab biosimilar - AM-001 - ASKP-1240 - AVX-001 - betamethasone maxacalcitol - bimekizumab - brodalumab - BTT-1023 - calcipotriene - CF-101 - CIR-001 - CT-327 - dalazatide - DFD-01 - DFD-06 - dimethyl fumarate - DLX-105 - DRM-02 - etanercept biosimilar - GK-664S - GR-MD-02 - guselkumab - IDP-118 - IMO-8400 - infliximab biosimilar - INV-103 - KD-025 - LEO-32731 - LP-0113 - M-801801 - MOL-4239 - MOL-4249 For more information visit http://www.researchandmarkets.com/research/7t..._psoriasis
PFE: 35.82 (-0.29), GALT: 2.56 (-0.09), AMGN: 176.44 (+1.64), MNTA: 23.12 (+1.07), CHRS: 35.40 (+0.73), PVCT: 0.50 (unch), CANF: 1.88 (-0.06), JNJ: 100.52 (+0.72), IDRA: 3.32 (-0.17), DERM: 22.08 (-0.38), FWP: 33.05 (+0.08)
37.6% Return Seen to Date on SmarTrend Charming Shoppes Call (CHRS)
Comtex SmarTrend(R) - Tue Jul 14, 4:46PM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 37.55% as of today's recent price of $34.45.
CHRS: 35.40 (+0.73)
Coherus Biosciences (CHRS) in Focus: Stock Surges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 13, 8:18AM CDT
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares surge around 11% on the day.
ACHN: 8.11 (unch), CHRS: 35.40 (+0.73)
$1.5 Trillion Reasons to Invest in These Companies
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 12, 10:02AM CDT
Source: Flickr user Bill Brooks Runaway healthcare spending poses a major risk to Americans, but generic drugs have been responsible for cutting $1.5 trillion in costs over the past 10 years, according to IMS Health data. That's an astounding...
BIIB: 335.41 (+5.03), ESRX: 90.75 (+1.44), BAX: 42.13 (+1.82), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), MNTA: 23.12 (+1.07), NVS: 103.25 (-0.32), CHRS: 35.40 (+0.73)
Global Neutropenia Pipeline Report 2015 - 20 Companies & 14 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d42lrx/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Apotex, Inc. - Biocon Limited - Biosidus S.A. - Cellerant Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Coherus BioSciences, Inc. - CSL Limited - Gamida Cell Ltd. - Genexine, Inc. - Inbiopro Solutions Pvt. Ltd. - Ligand Pharmaceuticals, Inc. - NAL Pharmaceuticals Ltd. - Pfenex Inc. - Richter Gedeon Nyrt. - Sandoz International GmbH - Taiho Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Therapeutic Proteins International, LLC - Toko Pharmaceutical Industries Co., Ltd. - USV Limited Drug Profiles - (piperacillin sodium tazobactam sodium) - ACN-8337 - CSL-324 - filgrastim (recombinant) - GC-003 - granulocyte colony-stimulating factor biobetter - GXG-3 - IBPB-004IG - LG-7455 - lipegfilgrastim - pegfilgrastim - romyelocel-L - ST-7 - tamibarotene For more information visit http://www.researchandmarkets.com/research/d4...eutropenia
TEVA: 71.19 (+0.50), PFNX: 20.56 (-0.30), CHRS: 35.40 (+0.73)
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), MNTA: 23.12 (+1.07), CHRS: 35.40 (+0.73), JNJ: 100.52 (+0.72), ALDR: 44.74 (-0.43), ABBV: 70.30 (+0.35), NVS: 103.25 (-0.32), CELGZ: 2.01 (+0.07)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 100.52 (+0.72), ALDR: 44.74 (-0.43), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), NVS: 103.25 (-0.32), CHRS: 35.40 (+0.73), CELGZ: 2.01 (+0.07)
14.8% Return Seen to Date on SmarTrend Charming Shoppes Call (CHRS)
Comtex SmarTrend(R) - Tue Jul 07, 12:03PM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 2 months, Charming Shoppes has returned 14.75% as of today's recent price of $28.74.
CHRS: 35.40 (+0.73)
Shares of CHRS Up 13.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 30, 11:47AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 1 month, Charming Shoppes has returned 13.16% as of today's recent price of $28.34.
CHRS: 35.40 (+0.73)
InsiderInsights.com Daily Round Up 6/16/15: RAI, GAIN, NPS, VRX
InsiderInsights - at Seeking Alpha - Wed Jun 17, 1:54PM CDT
RAI: 87.96 (+0.13), UCP: 7.39 (-0.05), CLMS: 12.00 (-0.08), DEA: 15.63 (-0.03), ANET: 84.59 (+1.65), VRX: 262.52 (+2.54), NATR: 13.02 (+0.07), COTY: 28.32 (+0.83), SAM: 233.22 (-1.56), DHIL: 190.80 (+0.54), SERV: 36.45 (+0.23), PCLN: 1,351.21 (+67.22), CHRS: 35.40 (+0.73), DXCM: 85.95 (+1.02), COMM: 31.54 (+0.42), RCPT: 228.97 (+0.97), RNG: 19.44 (+0.05), MNR: 9.95 (-0.05), GAIN: 7.90 (unch)
Charming Shoppes Shares Up 8.2% Since SmarTrend's Buy Recommendation (CHRS)
Comtex SmarTrend(R) - Thu Jun 11, 10:33AM CDT
SmarTrend identified an Uptrend for Charming Shoppes (AMEX:CHRS) on May 19th, 2015 at $25.05. In approximately 3 weeks, Charming Shoppes has returned 8.25% as of today's recent price of $27.11.
CHRS: 35.40 (+0.73)
Coherus Biosciences (CHRS) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 11, 8:17AM CDT
Coherus Biosciences (CHRS) is Overbought: Is A Drop Coming?
CHRS: 35.40 (+0.73)
Febrile Neutropenia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 10:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cgxl67/febrile) has announced the addition of the "Febrile Neutropenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Apotex - Biocon - Coherus BioSciences - Pfizer - Richter Gedeon - Sandoz International - Teva Pharmaceutical Industries - Therapeutic Proteins International - Xenetic Biosciences For more information visit http://www.researchandmarkets.com/research/cgxl67/febrile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TEVA: 71.19 (+0.50), CHRS: 35.40 (+0.73)
Coherus BioSciences to Present at Jefferies Healthcare Conference on June 3
GlobeNewswire - Wed May 27, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3rd at 3:00 pm ET in New York City.
CHRS: 35.40 (+0.73)
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results
GlobeNewswire - Mon May 11, 3:05PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the first quarter ended March 31, 2015.
CHRS: 35.40 (+0.73)
Next Week In Biotech: ASCO Abstracts, Pernix PDUFA, Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 8:00AM CDT
Biotech investors have plenty to look forward to next week, as the American Society of Clinical Oncology will release presentation abstracts for its upcoming annual meeting, while a PDUFA date is expected for Pernix (NASDAQ: PTX ). Last week's flood...
ARWR: 6.77 (+0.74), CLSN: 2.21 (-0.05), CMRX: 57.43 (+1.19), SCLN: 9.15 (+0.04), ELOS: 10.15 (-0.20), ZGNX: 19.13 (-0.36), LGND: 111.25 (+1.94), DEPO: 30.84 (+0.04), IMUC: 0.46 (-0.01), ARGS: 6.05 (-0.01), OPXA: 0.39 (-0.01), FLML: 21.97 (-1.08), OGXI: 3.05 (-0.14), CTSO: 6.82 (+0.02), DARA: 0.82 (+0.02), ICCC: 10.49 (+0.42), ICPT: 260.13 (+0.04), PBYI: 90.21 (+1.76), BDSI: 7.81 (+0.17), ACT: 298.98 (-2.94), DRNA: 11.54 (-0.43), BSTC: 63.13 (-1.84), PAHC: 39.31 (+0.62), PTX: 4.72 (-0.18), XON: 68.71 (+3.37), FOMX: 11.03 (+0.02), CLDN: 1.22 (unch), BIOC: 2.40 (+0.03), CHRS: 35.40 (+0.73), DSCI: 7.01 (-0.01), INO: 7.18 (+0.03), FMI: 21.17 (-0.19), CYTX: 0.42 (unch), ANTH: 10.94 (+0.23), ATHX: 1.04 (-0.03), ALQA: 5.14 (+0.07), ENDP: 85.85 (+0.74), DPLO: 47.75 (-1.98), GALT: 2.56 (-0.09), RPRX: 8.01 (+0.44), OMER: 15.77 (+0.15), HALO: 23.42 (+0.11), IDRA: 3.32 (-0.17), CF: 61.62 (+1.09), BTX: 3.06 (-0.05), APRI: 1.30 (-0.10), ATRS: 2.07 (-0.02), KPTI: 22.35 (+0.65)
